Immunotherapy-TKI Combo More Effective for Intermediate-Risk RCC – Renal and Urology News
Investigators question the usefulness of TKI-IO combinations in poor-risk disease.
Investigators question the usefulness of TKI-IO combinations in poor-risk disease.
The glucagon-like peptide-1 receptor agonist showed strong renoprotective effects in separate phase 3 clinical trials, FLOW and SELECT.
Regarding patient-reported outcomes, those who underwent URS showed higher urinary symptoms, greater pain intensity, and greater pain interference at 1 week following surgery compared with…
Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative…
Michael S. Cookson, MD, MMHC, FACS, recaps several presentations on prostate cancer from the 2024 American Urological Association Annual Meeting in San Antonio, Texas.
Comprehensively studying metabolism requires the measurement of metabolite levels. However, in contrast to the broad availability of gene expression data, metabolites are rarely measured in…
What is it like during the EAU-USANZ Trainee Week? Dr. Victoria Mari and Dr. Wouter van der Sanden share their experience as participants in this…
“If approved by the FDA, this new product will have a significant impact on prostate cancer patients, physicians, and their caregivers by helping to eliminate…
The European Association of Urology (EAU) Renal Transplantation Guidelines aim to provide a comprehensive overview of the medical and technical aspects relating to renal transplantation.
The prevalence of testosterone deficiency varies from 12% to 39% across men in their 50s to 80s. Urologists offer insights into management and more.
Findings have implications for counseling patients treated with radiation therapy plus ADT in routine clinical practice.